zoledronic acid has been researched along with Neoplasms in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.68) | 18.2507 |
| 2000's | 49 (33.33) | 29.6817 |
| 2010's | 74 (50.34) | 24.3611 |
| 2020's | 23 (15.65) | 2.80 |
| Authors | Studies |
|---|---|
| Chakhtoura, M; El-Hajj Fuleihan, G | 1 |
| Han, M; Hwang, HJ; Im, HJ; Kim, H; Kim, M; Kim, N; Koh, KN | 1 |
| Gupta, S; Mount, DB; Nigwekar, SU; Portales-Castillo, I; Rennke, HG; Yu, EW | 1 |
| Shane, E; Walker, MD | 1 |
| Lopes, MG; McNaught, KA; Morris, JS; Tosi, G | 1 |
| Assy, L; Attia, M; Khalil, SM; Salem, ML | 1 |
| Bassatne, A; Drake, MT; El-Hajj Fuleihan, G; Murad, MH; Piggott, T; Rahme, M | 1 |
| Adibi, R; Gheisari, Y; Moein, S | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Cho, SY; Hwang, JE; Jeon, YJ; Jeong, SM; Kim, HS; Yang, SJ; Yoo, BM | 1 |
| Cao, Y; Chen, Q; Dou, X; Qiao, B; Ran, H; Wang, Z; Xie, Z; Xu, L; Zhang, L | 1 |
| Bold, A; Gross, H; Hoeres, T; Holzmann, E; Knop, S; Wilhelm, M | 1 |
| Camen, A; Ciobanu, GA; Georgescu, CC; Ionescu, M; Mercuț, R; Mogoantă, L; Munteanu, CM; Popescu, SM; Scrieciu, M; Staicu, IE; Vlad, D | 1 |
| Baranyi, M; Hegedûs, B; Molnár, E; Rittler, D; Tímár, J | 1 |
| Bornstein, MM; Díaz-Parreño, SA; Helm, A; Limones, A; Molinero-Mourelle, P; Sáez-Alcaide, LM | 1 |
| Aspord, C; Chaperot, L; Charles, J; Girard, P; Ponsard, B | 1 |
| Deng, Y; Lai, X; Liu, M; Liu, X; Luo, X; Song, Y; Sui, D; Sun, W; Tang, X; Wang, S; Zhang, H; Zhao, D | 1 |
| de Alexandria Santos, DS; de Sales Lima, MV; E Silva de Carvalho, LFDC; Kitakawa, D; Magalhães, NC; Peralta, FDS; Scherma, ADP | 1 |
| Jayaram, R; O'Donnell, PW; Puleo, DA | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Aehnlich, P; Holmen Olofsson, G; Idorn, M; Pedersen, SR; Svane, IM; Thor Straten, P | 1 |
| Lin, Y; Qiu, H; Zhao, J | 1 |
| Funahara, M; Hayashida, S; Iwai, H; Kojima, Y; Murata, M; Otsuru, M; Saito, T; Sawada, S; Soutome, S; Umeda, M; Yanamoto, S | 1 |
| Bastida, C; Chaguaceda, C; Creus-Baró, N; Manzaneque, A; Mensa, M | 1 |
| Brezina, T; Cristino, J; Finek, J; Giannopoulou, C; Jandova, P; Kolek, M; Lothgren, M; Pásztor, B; Qian, Y | 1 |
| Raje, NS; Yee, AJ | 1 |
| Aoi, T; Azuma, T; Koyanagi-Aoi, M; Taniguchi-Ikeda, M; Watanabe, D; Yoshida, Y | 1 |
| Campani, V; Caraglia, M; De Rosa, G; Grillo, I; Luciani, P; Lusa, S; Ristori, S; Steiniger, F; Thamm, J; Valentino, G | 1 |
| Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
| Li, M; Lu, Y; Mao, C; Wan, P; Wang, W; Yang, K; Zhang, Y; Zhu, Y | 1 |
| Bi, F; Dai, X; Tang, Q; Xia, H; Zhou, S | 1 |
| Bafaloukos, D; Karagianni, A; Linardou, H; Michalakakou, K; Nicolatou-Galitis, O; Papadopoulou, E; Papassotiriou, I; Tarampikou, A; Tsixlakis, K; Vardas, E | 1 |
| Levêque, D | 1 |
| Lightowlers, S; Patterson, D | 1 |
| Atsuta, I; Chen, C; Le, AD; Liu, S; Shi, S; Zhang, Q | 1 |
| Coleman, RE; Young, RJ | 1 |
| Dudek, AZ; Zwolak, P | 1 |
| Abe, M; Kawazoe, K; Kujime, T; Minakuchi, K; Okada, N; Shinohara, Y; Teraoka, K | 1 |
| Body, JJ; Braun, A; Brown, JE; Chung, K; Cleeland, CS; Damyanov, D; Egerdie, B; Fallowfield, LJ; Marx, G; Palazzo, FG; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R | 1 |
| Azérad, J; Baaroun, V; Berdal, A; Charpentier, E; Coudert, AE; Descroix, V; Goudot, P; Javelot, MJ; Lescaille, G; Ostertag, A; Ruhin, B; Spano, JP; Tolédo, R | 1 |
| Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H | 1 |
| Gao, J; Ge, H; Gu, LQ; He, Q; Huang, ZS; Li, D; Liu, J; Liu, W; Su, L; Xu, J | 1 |
| Berk, V; Cetin, M; Elmali, F; Enhos, S; Eser, B; Inanc, M; Karaca, H; Kaynar, L; Ozkan, M; Pala, C; Sıvgın, S | 1 |
| Chang, Y; Guo, G; He, X; Li, F; Li, L; Li, M; Su, D; Wang, W | 1 |
| Maekawa, R; Nakatsura, T; Nieda, M; Takahara, M; Tomiyama, M; Yoshikawa, T | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| D'Haese, PC; McKenna, CE; Sun, S; Verhulst, A | 1 |
| Guo, H; Hartman, Z; Hobeika, A; Liu, CX; Lyerly, HK; Morse, MA; Nagaoka, K; Osada, T; Roy Choudhury, K; Takahara, M; Yang, XY | 1 |
| Koy, J; Koy, S; Lauer, G; Ney, M; Sabatowski, R; Schubert, M | 1 |
| Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R | 1 |
| Ananth, CV; Burke, WM; Chen, L; Hershman, DL; Hou, JY; Neugut, AI; Richards, CA; Tergas, AI; Wright, JD | 1 |
| Galiti, D; Galitis, E; Karampeazis, A; Labropoulos, S; Migliorati, C; Nicolatou-Galitis, O; Razis, E; Sgouros, J; Tsimpidakis, A | 1 |
| Cayrol, C; Duault, C; Familliades, J; Fournié, JJ; Franchini, DM; Girard, JP; Poupot, M; Roga, S | 1 |
| Kajizono, M; Kitamura, Y; Matsuoka, J; Sada, H; Sendo, T; Soga, Y; Sugiura, Y | 1 |
| Alexeeva, Y; Balakumaran, A; Braun, A; Facon, T; Feng, A; Hungria, V; Raje, N; Roodman, GD; Spencer, A; Stewart, AK; Terpos, E; Vadhan-Raj, S; Willenbacher, W | 1 |
| Abdi, E; Chern, B; Copeman, MC; Cosolo, W; Khalafallah, AA; Slancar, M; Woodfield, RJ | 1 |
| Morita, CT; Nada, MH; Tanaka, Y; Wang, H; Workalemahu, G | 1 |
| Ascani, L; Bareggi, C; Brunelli, C; Campa, T; Cislaghi, E; Fagnoni, E; Maniezzo, M; Ripamonti, CI; Saibene, G | 1 |
| Abati, S; Carmagnola, D; Celestino, S | 1 |
| Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
| Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS | 1 |
| Mitrofan, LM; Mönkkönen, J; Pelkonen, J | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Del Prete, S; Marra, M; Santini, D; Tagliaferri, P; Tassone, P; Tonini, G | 1 |
| Aksoy, S; Altundag, K; Arslan, C; Dede, DS; Dizdar, O; Harputluoglu, H | 1 |
| Chen, YM; Saad, F; Tchekmedyian, NS | 1 |
| Clézardin, P | 1 |
| Arnold, RM; Weinstein, E | 1 |
| McCauley, LK; Van Poznak, C; Yamashita, J | 1 |
| López-Carrizosa, MC; Pérez, AR; Samper-Ots, PM | 1 |
| Ariyoshi, N; Fujimoto, K; Goto, S; Kamigaki, T; Kaneko, T; Noguchi, A; Ozawa, M; Saito, M | 1 |
| Green, J; Lipton, A | 1 |
| Dowell, JE; Jean, GW; Keisner, SV; Shah, SR; Ussery, SM | 1 |
| Coleman, R; Cook, R; Hirsh, V; Lipton, A; Major, P | 1 |
| Costa, L; Dansey, R; Goldwasser, F; Henry, DH; Hirsh, V; Hungria, V; Jiang, Q; Jun, S; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Wang, J; Willenbacher, W; Woll, PJ; Yeh, H | 1 |
| Coleman, RE; Costa, L; Harper, P; Lipton, A | 1 |
| Bosch-Barrera, J; Menéndez, JA; Merajver, SD; Van Poznak, C | 1 |
| Weintraub, B | 1 |
| Barbounis, V; Boziari, P; Karayianni, A; Kyrtsonis, MC; Migliorati, CA; Nicolatou-Galitis, O; Papadopoulou, E; Repousis, P; Sarri, T | 1 |
| Lockhart, AC; Sorscher, SM | 1 |
| Legrand, SB | 1 |
| Cannon, MJ; Goyne, H; Stone, PJ | 1 |
| Lipton, A | 1 |
| Hirai, M; Kadowaki, N; Kitawaki, T | 1 |
| Hagi, T; Mattarollo, SR; Nicol, AJ; Nieda, M; Suzuki, K; Tokuyama, H; Yokokawa, K | 1 |
| Katano, M; Morisaki, T; Onishi, H; Yamasaki, A | 1 |
| Altvater, B; Juergens, H; Kailayangiri, S; Landmeier, S; Pscherer, S; Rossig, C; Savoldo, B | 1 |
| Barrios, CH; Brown, JE; Carrière, P; Daniels, A; Dansey, R; Diel, IJ; Facon, T; Fizazi, K; Henry, DH; Ibrahim, T; Saad, F; Senecal, F; Shore, N; Stemmer, SM; Stopeck, AT; Takahashi, S; Van Poznak, C; Zhou, L | 1 |
| Metcalf, S; Morgan, R; Pandha, HS | 1 |
| Bonacina, R; Mariani, U; Villa, A; Villa, F | 1 |
| Body, JJ | 3 |
| Bundred, N | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
| Henk, H; Kaura, S; Teitelbaum, A | 1 |
| Dranitsaris, G; Hatzimichael, E | 1 |
| Basi, DL; Dudek, AZ; Gopalakrishnan, R; Huckabay, S; Hughes, PJ; Leach, JW; Lunos, S; Swenson, KK; Thumbigere-Math, V; Tu, L | 1 |
| Clezardin, P; Coleman, R; Gnant, M; Morgan, G | 1 |
| Lopez-Olivo, MA; Peddi, P; Pratt, GF; Suarez-Almazor, ME | 1 |
| Gou, J; Tang, X; Zhang, K | 1 |
| D'Arcy, P; Hu, J; Lidén, M; Lundqvist, A; Rolny, C; Sarhan, D; Wennerberg, E; Winqvist, O | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Cha, YJ; Lee, YJ | 1 |
| Major, P | 1 |
| Berenson, JR | 1 |
| Theriault, RL | 1 |
| de Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, JJ; Tchekmedyian, S; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Davis, LE; Li, EC | 1 |
| Fraser, WD; Mishra, V; Peter, R | 1 |
| Figgitt, DP; Perry, CM | 1 |
| Duwe, S; Jürgens, H; Pscherer, S; Rischer, M; Rossig, C; Vormoor, J | 1 |
| Tanvetyanon, T | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Smith, M; Zheng, M | 1 |
| Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y | 1 |
| Kimura, S; Kiyono, Y; Kuroda, J; Maekawa, T; Matsumoto, S; Nogawa, M; Sato, K; Segawa, H; Wada, H; Yokota, A; Yuasa, T | 1 |
| Guarino, MJ; Hill, CE; Patel, K | 1 |
| Galanos, A; Katsouda, E; Kelekis, A; Mystakidou, K; Parpa, E; Vlahos, L | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Smith, MR | 1 |
| Bagan, JV; Diaz, JM; Hernandez, S; Jimenez, Y; Murillo, J; Poveda, R; Sanchis, JM; Scully, C | 1 |
| Bess, AL; Hohneker, JA | 1 |
| Suzuki, M; Tomoo, T | 1 |
| Bian, SG; Jiang, ZF; Shen, G; Song, ST; Wang, JJ; Wang, YJ; Xie, GR | 1 |
| Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T | 1 |
| Angeletti, S; Brown, JE; Budillon, A; Caraglia, M; Coleman, RE; Dicuonzo, G; Hannon, RA; Holen, I; La Cesa, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Baldini, E; Berto, P; Cortesi, E; Dauria, G; Roila, F; Schivazappa, C | 1 |
| Bertieri, R; Boccadoro, M; Bruno, B; Castella, B; Fiore, F; Foglietta, M; Mariani, S; Massaia, M; Nuschak, B; Pantaleoni, F | 1 |
| Jawad, AS; Shenker, NG | 1 |
| Angeletti, S; Battistoni, F; Caraglia, M; Dicuonzo, G; Galluzzo, S; Rocci, L; Santini, D; Schiavon, G; Tonini, G; Uzzalli, F; Venditti, O; Vincenzi, B | 1 |
| Brown, JE; Coleman, RE; Ellis, SP; Gutcher, S; Khanna, T; Lester, JE; McCloskey, E; Purohit, OP | 1 |
| Choong, PF; Dass, CR; Tran, TM | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Papaldo, P; Tomao, S | 1 |
| Abu-Id, MH; Acil, Y; Gottschalk, J; Kreusch, T; Russo, PA; Springer, I; Warnke, PH; Wiltfang, J | 1 |
| Dodson, TB; Wessel, JH; Zavras, AI | 1 |
| Body, JJ; Ford, J; Lortholary, A; Romieu, G; Vigneron, AM | 1 |
| Berenson, JR; Conde, F; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Vescio, R; Von Teichert, JM | 1 |
| Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F | 1 |
| Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M | 1 |
| Cheer, SM; Noble, S | 1 |
| Lortholary, A | 1 |
| Schwetz, BA | 1 |
| Davidson, TG | 1 |
| Heatley, S | 1 |
46 review(s) available for zoledronic acid and Neoplasms
| Article | Year |
|---|---|
Treatment of Hypercalcemia of Malignancy.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Zoledronic Acid | 2021 |
Hypercalcemia: A Review.
Topics: Calcium; Coma; COVID-19; Dehydration; Denosumab; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Immune Checkpoint Inhibitors; Nausea; Neoplasms; Pamidronate; Parathyroid Hormone; SARS-CoV-2; Sleepiness; Sodium Chloride Symporter Inhibitors; Vitamin A; Vitamin D; Vomiting; Zoledronic Acid | 2022 |
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Topics: Adult; Cross-Sectional Studies; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Quality of Life; Zoledronic Acid | 2023 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Neoplasms; Zoledronic Acid | 2020 |
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Osteoclasts; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2018 |
Antineoplastic activity of zoledronic acid and denosumab.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2013 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Interdisciplinary Communication; Intersectoral Collaboration; Male; Middle Aged; Neoplasms; Osteoporosis; Plasmacytoma; Risk Factors; Tooth Extraction; Treatment Outcome; Zoledronic Acid | 2015 |
Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
Topics: Aged; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Neoplasms; Periodontal Diseases; Radiography, Panoramic; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2015 |
Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Drug Delivery Systems; Drug Synergism; Humans; Imidazoles; Models, Biological; Neoplasms; Zoledronic Acid | 2009 |
[Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2010 |
Updates on osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Neoplasms; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Anticancer properties of zoledronic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2010 |
Zoledronic acid use in cancer patients: more than just supportive care?
Topics: Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasms; Osteolysis; Zoledronic Acid | 2011 |
Anticancer evidence for zoledronic acid across the cancer continuum.
Topics: Bone Density Conservation Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Male; Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2011 |
Modern management of malignant hypercalcemia.
Topics: Bone Density Conservation Agents; Calcitonin; Clinical Protocols; Diphosphonates; Fluid Therapy; Gallium; Humans; Hypercalcemia; Imidazoles; Neoplasms; Palliative Care; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid | 2011 |
Zoledronic acid: multiplicity of use across the cancer continuum.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Zoledronic Acid | 2011 |
[Therapy for malignancies and inflammatory disorders by modulating human dendritic cell functions].
Topics: Cancer Vaccines; Cell- and Tissue-Based Therapy; Cells, Cultured; Dendritic Cells; Diphosphonates; Humans; Imidazoles; Immunotherapy; Inflammation; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Neoplasms; WT1 Proteins; Zoledronic Acid | 2011 |
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Topics: Algorithms; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2012 |
Antiangiogenic effects of zoledronate on cancer neovasculature.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Neoplasms; Neovascularization, Pathologic; Zoledronic Acid | 2011 |
Denosumab for the management of bone disease in patients with solid tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Management; Humans; Imidazoles; Immunologic Factors; Neoplasm Metastasis; Neoplasms; Outcome Assessment, Health Care; Palliative Care; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2012 |
Antiresorptive therapies in oncology and their effects on cancer progression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Controlled Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; RANK Ligand; Zoledronic Acid | 2012 |
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Europe; Health Care Costs; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Delivery Systems; Endpoint Determination; Female; Humans; Imidazoles; Male; Neoplasms; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2012 |
Effects of bone-targeted agents on cancer progression and mortality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2013 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Zoledronic acid (Zometa) use in bone disease.
Topics: Bone Diseases; Diphosphonates; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2003 |
Zoledronic acid: a new parenteral bisphosphonate.
Topics: Animals; Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Metabolic Clearance Rate; Neoplasms; Zoledronic Acid | 2003 |
Hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Diphosphonates; Forecasting; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid | 2004 |
Zoledronic acid: a review of its use in patients with advanced cancer.
Topics: Area Under Curve; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Drug Tolerance; Economics, Pharmaceutical; Female; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2004 |
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2005 |
Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2006 |
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Cells, Cultured; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Geranyltranstransferase; Humans; Hypercalcemia; Imidazoles; Neoplasms; Osteoclasts; Zoledronic Acid | 2005 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Neoplasms; Osteoporosis; Pamidronate; Risk Factors; Zoledronic Acid | 2006 |
Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diphosphonates; Endostatins; Eye Proteins; Humans; Imidazoles; Neoplasms; Neovascularization, Pathologic; Nerve Growth Factors; Serpins; Zoledronic Acid | 2007 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2000 |
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2001 |
Zoledronic acid.
Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Zoledronic Acid | 2001 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematologic Neoplasms; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Prognosis; Recurrence; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2001 |
Conventional treatment of hypercalcemia of malignancy.
Topics: Calcitonin; Clinical Protocols; Diphosphonates; Drug Costs; Fluid Therapy; Gallium; Humans; Hydrocortisone; Hypercalcemia; Imidazoles; Neoplasms; Nucleic Acid Synthesis Inhibitors; Plicamycin; Prednisone; Rehydration Solutions; Zoledronic Acid | 2001 |
Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pain; Zoledronic Acid | 2001 |
19 trial(s) available for zoledronic acid and Neoplasms
| Article | Year |
|---|---|
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Topics: Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Cost-Benefit Analysis; Czech Republic; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Neoplasms; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid | 2017 |
Identification of the risk factors associated with hypocalcemia induced by denosumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Calcium; Creatinine; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteoclasts; RANK Ligand; Retrospective Studies; Risk Factors; ROC Curve; Zoledronic Acid | 2013 |
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2014 |
An effective therapy to painful bone metastases: cryoablation combined with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Cryosurgery; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pain; Prognosis; Prospective Studies; Zoledronic Acid | 2014 |
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid | 2015 |
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2016 |
Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Neoplasms; Prospective Studies; Zoledronic Acid | 2018 |
Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Feasibility Studies; Female; Humans; Imidazoles; Immunotherapy; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2011 |
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasms; RANK Ligand; Survival Rate; Treatment Outcome; Young Adult; Zoledronic Acid | 2011 |
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
Topics: Aged; Diphosphonates; Feasibility Studies; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; T-Lymphocytes; Treatment Outcome; Zoledronic Acid | 2011 |
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Topics: Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Placebos; Zoledronic Acid | 2003 |
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.
Topics: Aged; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2005 |
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
Topics: Adjuvants, Immunologic; Bone Density Conservation Agents; Cancer Vaccines; Cell Proliferation; Cells, Cultured; Dendritic Cells; Diphosphonates; Histocompatibility Antigens; Humans; Imidazoles; Immunity, Innate; Immunologic Memory; Immunotherapy, Adoptive; Lymphocyte Activation; Monocytes; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Time Factors; Zoledronic Acid | 2007 |
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
Topics: Absorptiometry, Photon; Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 2007 |
A dose-finding study of zoledronate in hypercalcemic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 1999 |
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Topics: Adult; Aged; Anorexia; Biomarkers; Bone Neoplasms; Bone Resorption; Constipation; Diphosphonates; Female; Fever; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2001 |
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors; Zoledronic Acid | 2001 |
82 other study(ies) available for zoledronic acid and Neoplasms
| Article | Year |
|---|---|
Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
Topics: Animals; Antigens, CD19; Antigens, Neoplasm; Cell Culture Techniques; Cell Line, Tumor; Cells, Cultured; Humans; Immunotherapy, Adoptive; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Receptors, Chimeric Antigen; T-Lymphocyte Subsets; Zoledronic Acid | 2021 |
Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.
Topics: Acute Kidney Injury; Amino Acids; Bicarbonates; Bone Density Conservation Agents; Fanconi Syndrome; Humans; Neoplasms; Zoledronic Acid | 2022 |
Retrospective assessment of tolerability and efficacy of zoledronate in the palliative treatment of cancer-bearing dogs.
Topics: Animals; Calcium; Dog Diseases; Dogs; Hypercalcemia; Neoplasms; Pain; Palliative Care; Retrospective Studies; Zoledronic Acid | 2023 |
IL-12 conditioning of peripheral blood mononuclear cells from breast cancer patients promotes the zoledronate-induced expansion of γδ T cells in vitro and enhances their cytotoxic activity and cytokine production.
Topics: Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Imidazoles; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid | 2023 |
Zoledronic acid targets chemo-resistant polyploid giant cancer cells.
Topics: Cell Line, Tumor; Cisplatin; Giant Cells; Humans; Neoplasms; Polyploidy; Reactive Oxygen Species; Zoledronic Acid | 2023 |
WT1 Pulsed Human CD141+ Dendritic Cell Vaccine Has High Potential in Solid Tumor-Targeted Immunotherapy.
Topics: Cancer Vaccines; Dendritic Cells; Humans; Immunotherapy; Neoplasms; T-Lymphocytes, Cytotoxic; Vaccines; WT1 Proteins; Zoledronic Acid | 2023 |
Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Topics: CD8-Positive T-Lymphocytes; Cytokines; Humans; Immunotherapy; Macrophages; Neoplasms; Peptides; Tumor Microenvironment; Tumor-Associated Macrophages; Zoledronic Acid | 2023 |
An optimized cultivation method for future
Topics: Diphosphonates; Humans; Imidazoles; Interleukin-2; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid | 2023 |
Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.
Topics: Humans; Mandible; Neoplasms; Osteonecrosis; Quality of Life; Retrospective Studies; Zoledronic Acid | 2023 |
[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].
Topics: Cell Line, Tumor; Cell Survival; Diphosphonates; Humans; Mutation; Neoplasms; Prenylation; ras Proteins; Signal Transduction; Zoledronic Acid | 2019 |
Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.
Topics: Butyrophilins; Cell Communication; Cell Line, Tumor; Dendritic Cells; Humans; Immunotherapy; Infections; Interferon Type I; Interferon-gamma; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; T-Lymphocytes; Zoledronic Acid | 2020 |
Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Topics: Animals; Cell Line, Tumor; Humans; Immunotherapy; Macrophages; Mice; N-Acetylneuraminic Acid; Neoplasms; Sialic Acid Binding Immunoglobulin-like Lectins; Tumor Microenvironment; Tumor-Associated Macrophages; Zoledronic Acid | 2020 |
An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Middle Aged; Neoplasms; Osteonecrosis; Zoledronic Acid | 2020 |
Systems for local, sustained release of zoledronic acid as a potential treatment for metastatic bone disease.
Topics: Bone and Bones; Bone Diseases; Delayed-Action Preparations; Humans; Neoplasms; Zoledronic Acid | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
The capacity of CD4
Topics: Antigen-Presenting Cells; CD4-Positive T-Lymphocytes; Humans; Lymphocyte Activation; Male; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2021 |
Denosumab is not associated with risk of malignancy? More evidence is needed.
Topics: Denosumab; Humans; Neoplasms; Zoledronic Acid | 2021 |
Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Female; Humans; Jaw; Male; Middle Aged; Multivariate Analysis; Neoplasms; Osteonecrosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Tooth Extraction; Zoledronic Acid | 2021 |
Use and safety of denosumab in cancer patients.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Female; Follow-Up Studies; Guideline Adherence; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Practice Guidelines as Topic; Retrospective Studies; Tertiary Care Centers; Vitamin D; Zoledronic Acid | 2017 |
The Generation of Human γδT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture.
Topics: Cell- and Tissue-Based Therapy; Cells, Cultured; Cellular Reprogramming; Gene Transfer Techniques; Humans; Induced Pluripotent Stem Cells; Interleukin-2; Intraepithelial Lymphocytes; Lymphocyte Activation; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Sendai virus; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2018 |
Structural Characterization of Self-Assembling Hybrid Nanoparticles for Bisphosphonate Delivery in Tumors.
Topics: Antineoplastic Agents; Cryoelectron Microscopy; Drug Compounding; Fatty Acids, Monounsaturated; Humans; Liposomes; Microscopy, Electron, Transmission; Molecular Structure; Nanoparticles; Neoplasms; Neutron Diffraction; Phosphatidylethanolamines; Polyethylene Glycols; Quaternary Ammonium Compounds; Scattering, Small Angle; Transferrin; X-Ray Diffraction; Zoledronic Acid | 2018 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Topics: Alloys; Apoptosis; Biocompatible Materials; Bone and Bones; Bone Neoplasms; Calcium Phosphates; Cell Movement; Cytoskeleton; Diphosphonates; Giant Cell Tumor of Bone; Humans; Magnesium; Mitochondria; Neoplasm Metastasis; Neoplasms; NF-kappa B; Osteoclasts; Osteolysis; Oxidative Stress; Recurrence; Risk Factors; Signal Transduction; Strontium; Zoledronic Acid | 2018 |
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Topics: A549 Cells; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; HCT116 Cells; HT29 Cells; Humans; Mevalonic Acid; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2019 |
The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.
Topics: Aged; Aged, 80 and over; Bevacizumab; Biomarkers; Drug Therapy, Combination; Female; Gingival Crevicular Fluid; Humans; Inflammation; Interleukin-17; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Osteonecrosis; Periodontal Diseases; Periodontal Pocket; Predictive Value of Tests; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2020 |
[Dose reassessment: An answer to the high cost of drugs used in oncology?]
Topics: Abiraterone Acetate; Adenine; Antineoplastic Agents; Clinical Protocols; Dasatinib; Drug Costs; France; gamma-Glutamyl Hydrolase; Humans; Insurance, Pharmaceutical Services; Medical Oncology; Neoplasms; Nivolumab; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; United States; Zoledronic Acid | 2019 |
Mismanagement of malignant hypercalcaemia.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Malpractice; Neoplasms; Zoledronic Acid | 2013 |
IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Interleukin-17; Jaw; Macrophages; Mice; Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Transformation, Neoplastic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Metabolic Networks and Pathways; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2013 |
Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Risk Factors; Treatment Outcome; Zoledronic Acid | 2014 |
Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.
Topics: Amino Acid Sequence; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Imidazoles; Microscopy, Fluorescence; Models, Molecular; Molecular Sequence Data; Neoplasms; Quinolines; Zoledronic Acid | 2014 |
Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Follow-Up Studies; Gingival Crevicular Fluid; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Osteoprotegerin; Prognosis; RANK Ligand; Survival Rate; Zoledronic Acid | 2014 |
Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
Topics: Animals; Antigens, Neoplasm; Cell Adhesion Molecules; Cytomegalovirus; Diphosphonates; Glypicans; Humans; Imidazoles; Immunotherapy, Adoptive; Leukocytes, Mononuclear; Mice; Neoplasm Proteins; Neoplasms; Peptides; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.
Topics: Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Endocytosis; Humans; Imidazoles; Kidney Tubules; Models, Biological; Neoplasms; Zoledronic Acid | 2015 |
Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Topics: Animals; Antigen Presentation; Cancer Vaccines; Carcinoembryonic Antigen; Cell Differentiation; Cell Proliferation; Dendritic Cells; Dinoprostone; Diphosphonates; Drug Therapy, Combination; HCT116 Cells; Humans; Imidazoles; Immunotherapy, Adoptive; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms; Picibanil; Precision Medicine; T-Lymphocytes; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2015 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pamidronate; Quality of Health Care; Treatment Outcome; Zoledronic Acid | 2015 |
TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
Topics: Antigens, CD; Butyrophilins; Cell Proliferation; Cells, Cultured; Diphosphates; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Immunotherapy; Interferon-gamma; Interleukin-2; Interleukin-33; Leukocytes, Mononuclear; Lymphocyte Activation; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Th1 Cells; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2016 |
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Topics: Aged; Anemia; Bone Density Conservation Agents; Bone Diseases; Denosumab; Dental Care; Diabetes Complications; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2015 |
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Topics: Adult; Animals; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-15; Interleukin-2; Intraepithelial Lymphocytes; Mice; Neoplasms; Tumor Burden; Zoledronic Acid | 2017 |
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Topics: Academies and Institutes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2009 |
Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Topics: Aged; Aged, 80 and over; Alveolar Bone Loss; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; DMF Index; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Periodontal Index; Pilot Projects; Retrospective Studies; Risk Factors; Stomatitis, Denture; Tooth Extraction; Zoledronic Acid | 2008 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid | 2009 |
The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Topics: Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Diphosphonates; Diterpenes; Drug Resistance, Neoplasm; Hemiterpenes; Humans; Imidazoles; Lovastatin; Membrane Potential, Mitochondrial; Neoplasms; Organophosphorus Compounds; Zoledronic Acid | 2009 |
Zoledronic acid and atrial fibrillation in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Electrocardiography; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Risk Factors; Smoking; Zoledronic Acid | 2011 |
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasms; Orchiectomy; Placebos; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2010 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neoplasms; Pain; Pamidronate; Renal Insufficiency; Zoledronic Acid | 2010 |
Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Prognosis; Prospective Studies; Statistics, Nonparametric; Zoledronic Acid | 2010 |
Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Time Factors; Zoledronic Acid | 2012 |
Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Cariostatic Agents; Chlorhexidine; Dental Prophylaxis; Diphosphonates; Female; Fluorides; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Longitudinal Studies; Male; Middle Aged; Neoplasms; Oral Hygiene; Osteonecrosis; Pain Measurement; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; RANK Ligand; ras Proteins; Treatment Outcome; Zoledronic Acid | 2011 |
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Cancer Vaccines; Clonal Anergy; Cyclophosphamide; Dendritic Cells; Diphosphonates; Female; Humans; Imidazoles; Immunosuppression Therapy; Immunotherapy, Active; Indoleamine-Pyrrole 2,3,-Dioxygenase; Macrophages; Neoplasms; Ovarian Neoplasms; Pamidronate; T-Lymphocytes, Regulatory; Th17 Cells; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Zoledronic Acid | 2011 |
Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigen Presentation; Carcinoembryonic Antigen; Cell Separation; Cells, Cultured; Diphosphonates; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Imidazoles; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Lymphocyte Count; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; Stomach Neoplasms; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2011 |
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Topics: Antigen Presentation; Antigens, Neoplasm; Autoantigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Diphosphonates; Epitopes, T-Lymphocyte; Flow Cytometry; HLA-A2 Antigen; Humans; Imidazoles; K562 Cells; Lymphocyte Activation; Neoplasms; Oxidoreductases; Peptides; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Transfection; Zoledronic Acid | 2012 |
Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Risk Factors; Zoledronic Acid | 2011 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Neoplasms; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2012 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Neoplasms; Osteonecrosis; Pamidronate; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Zoledronic Acid | 2012 |
Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].
Topics: Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Chemistry, Pharmaceutical; Diphosphonates; Drug Carriers; Humans; Imidazoles; Nanoparticles; Nanotechnology; Neoplasms; Patents as Topic; Phospholipids; Zoledronic Acid | 2012 |
Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Topics: Animals; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Diphosphonates; Gene Expression Regulation; Humans; Imidazoles; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Mice; Mice, SCID; Monocytes; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Contraindications; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hospitals, Teaching; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Practice Guidelines as Topic; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Zoledronic Acid | 2013 |
Severe hypocalcaemia after being given intravenous bisphosphonate.
Topics: Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 2004 |
Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Topics: Antigens, Neoplasm; Cell Division; Cytotoxicity, Immunologic; Diphosphonates; Epitopes, T-Lymphocyte; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Interferon-gamma; Lymphocyte Activation; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Retroviridae; T-Lymphocyte Subsets; Transduction, Genetic; Tumor Cells, Cultured; Zoledronic Acid | 2004 |
Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?
Topics: Angiogenesis Inhibitors; Calcium; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Models, Biological; Neoplasms; Neovascularization, Pathologic; Treatment Outcome; Zoledronic Acid | 2004 |
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Regeneration; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cohort Studies; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Peptides; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Zoledronic Acid | 2005 |
Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Random Allocation; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; T-Lymphocytes; Zoledronic Acid | 2005 |
Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Important drug precaution for dental health professionals with patients being treated for cancer.
Topics: Bone Density Conservation Agents; Contraindications; Dental Care; Diphosphonates; Humans; Imidazoles; Neoplasms; Osteonecrosis; Zoledronic Acid | 2005 |
[Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Safety; Zoledronic Acid | 2005 |
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2006 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study].
Topics: Bone Density Conservation Agents; Costs and Cost Analysis; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Neoplasms; Osteolysis; Pamidronate; Time and Motion Studies; Zoledronic Acid | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2007 |
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Prospective Studies; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |
Zoledronic acid and angiogenesis.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Neoplasms; Neovascularization, Pathologic; Zoledronic Acid | 2007 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Zoledronic Acid | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Logistic Models; Male; Multivariate Analysis; Neoplasms; Obesity; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Zoledronic Acid | 2008 |
From the Food and Drug Administration.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Diphosphonates; Equipment Reuse; Heart Failure; Humans; Hypercalcemia; Imidazoles; Natriuretic Peptide, Brain; Neoplasms; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |
New bisphosphonic acid approved by FDA.
Topics: Diphosphonates; Drug Approval; Humans; Hypercalcemia; Imidazoles; Neoplasm Proteins; Neoplasms; Parathyroid Hormone-Related Protein; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |